Interview with Fabian Dwyer, General Manager, IMS Health Australia
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Address: Suite 406, Kew Junction Tower, 89 High Street Kew, Vic 3101,Australia
Tel: +61 3 9455 1444
Web: http://www.imshealth.com.au/
With offices in Sydney, Melbourne and Auckland, IMS Health Australia is a trusted partner delivering solutions to local pharmaceutical and healthcare sectors.
IMS Health Australia captures information from a wide range of sources including pharmacies, hospitals, pharmaceutical wholesales, healthcare professionals, software suppliers and the pharmaceutical industry. This information is combined to give a complete picture of the market and is critical in business decisions such as assessing the impact of product launches or identifying new uses for existing therapies.
IMS Health Australia provides crucial insight into the pharmaceutical industry, healthcare manufacturers, distributors, government and healthcare agencies, academic institutions and research organizations. This information enables the development of medical education and information programs, rationale of the cost-effectiveness of drug therapies and evaluation of patient health outcomes in health policy decisions. This information is critical to both IMS Health Australia’s customers and supply partners and provides a clearer picture of the healthcare landscape.
IMS Health Australia is committed to servicing the information needs of the healthcare sector. IMS Health Australia offers a continuum of capabilities from information to analytics to consulting. With over 50 years experience and offices in more than 100 countries, IMS Health Australia is the leading source of global information for the pharmaceutical and healthcare industry.
Analytics, Research and development, Generics, Consulting
How have your experiences at Quintiles, Astra, Baxter, and Innovex – covering the spectrum from small to large pharma in addition to the service side – helped in managing IMS…
Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the…
A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean…
Regular contributor Brendan Shaw looks ahead to a potentially turbulent 2025 for the pharmaceutical industry, highlighting five key trends that industry stakeholders must carefully navigate over the coming 12 months.…
In his latest opinion piece, Shawview Consulting’s Brendan Shaw draws from classic sci-fi to reflect on the pros and cons of using artificial intelligence for health technology assessment. Shaw concludes…
Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes…
Shawview Consulting’s Brendan Shaw looks back on a sombre United Nations High Level Meeting on Universal Health Coverage in New York last month, as stakeholders reflected on the long road…
After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally…
Shawview Consulting’s Brendan Shaw casts his eye over the increased industry focus on Environment, Social, and Governance (ESG) issues in recent years, urging pharma companies to deliver on their ESG promises…
Brendan Shaw looks ahead to the rest of 2023, identifying five key trends to watch out for in the healthcare and life sciences sector. With the worst of COVID-19 now…
CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in…
A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research…
Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the…
See our Cookie Privacy Policy Here
